GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Apimeds Pharmaceuticals US APUS · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.70

-0.37%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$6.0m

FY2021FY2025

Free cash flow

−$9.0m

FY2021FY2025

Shareholders' equity

$153.3m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Gross profit−$5,706————
Research and development$1.6m—$98,544$368,000$489,939
Operating income−$5.8m−$1.3m−$747,436−$639,529−$1.0m
Net income−$6.0m−$1.4m−$777,694−$668,666−$1.0m
Diluted earnings per share-4.77-10.95-6.13-5.27-0.63

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assets$164.2m$13,057$422,076$6,171$172,169
Cash and short-term investments$3.6m$3,455$410,481$6,171$171,438
Total liabilities$10.8m$1.4m$390,205$719,777$410,652
Debt$7.8m$596,844$266,891$660,000$400,000
Shareholders' equity$153.3m−$1.4m$31,871−$713,606−$238,483
Shares outstanding1m0m0m0m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−$8.9m−$733,526−$627,790−$448,167−$823,114
Capital spending−$57,333————
Free cash flow−$9.0m−$733,526−$627,790−$448,167−$823,114

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit—−$20,044—−$1,489————
Operating income−$6.3m−$4.1m−$7.0m−$1.8m−$2.7m−$364,368−$275,613−$299,999
Net income−$20.2m−$35.1m−$1.2m−$1.8m−$2.7m−$402,397−$311,633−$332,521
Diluted earnings per share-12.35-21.47-0.92-1.42-2.12-0.32-2.46-2.62
Cash from operations−$6.0m−$2.0m−$3.0m−$1.0m−$3.0m———
Total assets$127.6m$141.2m$164.2m$9.3m$10.5m$259,904$13,057$36,907
Cash and short-term investments$278,371$2.5m—$7.0m$8.7m$250,342$3,455$26,571
Debt$14.5m$9.4m—$500,000$500,000$873,620$596,844$571,992
Shareholders' equity$106.4m$126.5m$153.3m$8.2m$9.7m−$1.8m−$1.4m−$1.0m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income108.8%——
Net income107.8%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-3.4

Share price return

Finished calendar years

2025
Return-20%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 24 Jul 2026
  • 10-to-1 reverse split · 26 Mar 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.